PathAI
2026
$1.1B
Why
Roche agreed in May 2026 to acquire Boston-based PathAI for $750 million upfront plus up to $300 million in milestones to strengthen AI-driven digital pathology.
F. Hoffmann-La Roche AG
Pharmaceuticals and DiagnosticsFounded 1896- HQ today: Basel, Switzerland
Reviewed by Swet Parvadiya
Company data updated: October 2026
Acquisitions
Roche Acquisitions
10
Major Deals Covered
$63.8B
Disclosed Deal Value
What are Roche's biggest acquisitions?
Roche's largest disclosed acquisition here is Genentech for $46.8B in 2009. This page covers 10 major deals from 1982 to 2026, each with its price where disclosed and the reason behind it.
- Major deals covered
- 10
- Largest deal
- Genentech ($46.8B)
- First deal
- 1982
- Most recent
- 2026
| Company | Year | Price | Purpose |
|---|---|---|---|
| Biomedical Reference Laboratories | 1982 | $163.5M | F. Hoffmann-La Roche acquired Biomedical Reference Laboratories in 1982 for $164 million. |
| Genentech | 2009 | $46.8B | Roche bought the roughly 44% of Genentech it did not already own for about $46.8 billion, after holding a majority stake since 1990. |
| Bina Technologies | 2014 | Undisclosed | F. Hoffmann-La Roche acquired Bina Technologies in 2014. |
| Adheron Therapeutics | 2015 | $105.0M | F. Hoffmann-La Roche acquired Adheron Therapeutics in 2015 for $105 million. |
| ForSight VISION4 | 2017 | Undisclosed | F. Hoffmann-La Roche acquired ForSight VISION4 in 2017. |
| Foundation Medicine | 2018 | $2.4B | Roche bought the remaining shares of Foundation Medicine it did not own, in a deal valued at about $2.4 billion, to add comprehensive genomic profiling. |
| Telavant | 2023 | $7.1B | Roche paid $7.1 billion upfront for Telavant to gain US and Japan rights to the anti-TL1A antibody RVT-3101 (afimkibart) for inflammatory bowel disease. |
| Carmot Therapeutics | 2023 | $2.7B | Roche paid $2.7 billion upfront for Carmot to enter obesity, adding the incretin candidate CT-388 (enicepatide). |
| 89bio | 2025 | $3.5B | Roche agreed in September 2025 to buy 89bio for $14.50 per share in cash plus a CVR of up to $6.00 per share, a total of up to about $3.5 billion, adding the MASH candidate pegozafermin. |
| PathAI | 2026 | $1.1B | Roche agreed in May 2026 to acquire Boston-based PathAI for $750 million upfront plus up to $300 million in milestones to strengthen AI-driven digital pathology. |
- What companies has Roche bought?
- Major acquisitions by Roche documented here include Genentech (2009), Telavant (2023), 89bio (2025), Carmot Therapeutics (2023) and Foundation Medicine (2018).
- What is Roche's most recent acquisition?
- The most recent Roche acquisition documented here is PathAI, in 2026, for $1.1B.
89bio
2025
$3.5B
Why
Roche agreed in September 2025 to buy 89bio for $14.50 per share in cash plus a CVR of up to $6.00 per share, a total of up to about $3.5 billion, adding the MASH candidate pegozafermin.
Telavant
2023
$7.1B
Why
Roche paid $7.1 billion upfront for Telavant to gain US and Japan rights to the anti-TL1A antibody RVT-3101 (afimkibart) for inflammatory bowel disease.
Carmot Therapeutics
2023
$2.7B
Why
Roche paid $2.7 billion upfront for Carmot to enter obesity, adding the incretin candidate CT-388 (enicepatide).
Foundation Medicine
2018
$2.4B
Why
Roche bought the remaining shares of Foundation Medicine it did not own, in a deal valued at about $2.4 billion, to add comprehensive genomic profiling.
Impact
This strategic, targeted acquisition immediately provided Roche with an established national presence in comprehensive genomic testing, allowing it to cross-sell its complex targeted cancer drugs to the exact right patients.
Outcome
Foundation Medicine became a core part of Roche's companion diagnostics and precision oncology strategy.
ForSight VISION4
2017
Why
F. Hoffmann-La Roche acquired ForSight VISION4 in 2017.
Adheron Therapeutics
2015
$105M
Why
F. Hoffmann-La Roche acquired Adheron Therapeutics in 2015 for $105 million.
Bina Technologies
2014
Why
F. Hoffmann-La Roche acquired Bina Technologies in 2014.
Genentech
2009
$46.8B
Why
Roche bought the roughly 44% of Genentech it did not already own for about $46.8 billion, after holding a majority stake since 1990.
Impact
This historic transaction instantly transformed Roche's scientific footprint, allowing it to integrate Genentech's advanced, innovative biotechnology pipeline directly into its global commercialization engine.
Outcome
Genentech became Roche's US research and commercial hub and the source of most of its oncology franchise.
Biomedical Reference Laboratories
1982
$164M
Why
F. Hoffmann-La Roche acquired Biomedical Reference Laboratories in 1982 for $164 million.
F. Hoffmann-La Roche AG's Growth & Acquisition Strategy
Roche is building a cardiovascular, renal and metabolic franchise through acquisitions of Carmot Therapeutics (2023, $2.7 billion upfront) and 89bio (2025, up to about $3.5 billion), the petrelintide partnership with Zealand Pharma, and a new Innovation Center in Boston opened in September 2026. It is also extending its immunology pipeline via Telavant (2023, $7.1 billion) and investing in AI diagnostics with the PathAI acquisition announced in May 2026 ($750 million upfront plus up to $300 million in milestones).
How F. Hoffmann-La Roche AG Makes Money
Roche makes money in two ways. The Pharmaceuticals Division (~$57.2 billion (CHF 47.7 billion) in 2025) sells patented medicines, mostly biologics, in oncology, neuroscience, immunology, ophthalmology and haemophilia; top growth drivers in 2025 were Phesgo, Xolair, Ocrevus, Hemlibra and Vabysmo. The Diagnostics Division (~$16.6 billion (CHF 13.8 billion)) places cobas, Elecsys and Ventana instruments in laboratories and earns recurring revenue from the reagents, tests and service contracts needed to run them. Companion diagnostics link the two: a Roche test can identify the patients most likely to benefit from a Roche drug.
Roche Acquisitions FAQ
What was the largest and most consequential acquisition in Roche's history?
Roche's landmark transaction was the full acquisition of Genentech for $46.8 billion in March 2009, buying the remaining 44% of shares it did not already own, cementing Roche as the undisputed global leader in oncology and biotechnology.
What was the Telavant acquisition and why did Roche pay $7.1 billion for it in 2023?
In October 2023, Roche acquired Telavant Holdings (previously owned by Roivant Sciences and Pfizer) for $7.1 billion in cash, gaining rights in the US and Japan to RVT-3101, a promising first-in-class Phase 3 TL1A antibody for ulcerative colitis and Crohn's disease.
Why did Roche acquire Carmot Therapeutics for $2.7 billion in 2023?
In December 2023, Roche acquired Carmot Therapeutics for $2.7 billion upfront (plus up to $400M in milestone payments) to acquire three clinical-stage GLP-1/GIP dual incretin assets (including CT-388 injectable and CT-996 pill) for obesity and type 2 diabetes.
When and why did Roche acquire Spark Therapeutics?
In December 2019, Roche acquired Philadelphia-based gene therapy pioneer Spark Therapeutics for $4.3 billion, acquiring Luxturna (the first FDA-approved gene therapy for inherited retinal blindness) and a proprietary adeno-associated virus (AAV) gene therapy platform for hemophilia.
What was the acquisition of Foundation Medicine?
In 2018, Roche completed the full acquisition of genomic profiling pioneer Foundation Medicine for $2.4 billion, integrating comprehensive genomic tumor sequencing (FoundationOne) into Roche's personalized oncology care platform.
Why did Roche acquire Flatiron Health for $1.9 billion in 2018?
Roche acquired Flatiron Health to harness real-world clinical oncology data from electronic health records, accelerating post-market drug surveillance and regulatory submissions with synthetic control arms.
What was the acquisition of Ventana Medical Systems in 2008?
In 2008, Roche acquired Ventana Medical Systems for $3.4 billion, establishing global market leadership in automated tissue-based cancer diagnostic instruments and slide-staining systems for anatomical pathology labs.
How did the acquisition of Cetus Corporation's PCR technology in 1991 reshape Roche?
Roche paid $300 million to Cetus Corporation in 1991 for the global patent rights to the Polymerase Chain Reaction (PCR) invented by Kary Mullis, creating Roche Molecular Systems and revolutionizing global diagnostics.
What was the acquisition of GenMark Diagnostics in 2021?
In March 2021, Roche acquired GenMark Diagnostics for $1.8 billion, expanding its molecular laboratory portfolio with syndromic panel testing that detects multiple pathogens from a single patient sample in under two hours.
What is Roche's core criteria when evaluating M&A targets?
Roche targets first-in-class or best-in-class scientific platforms that complement its Pharma therapeutic pillars (oncology, immunology, neuroscience, ophthalmology, cardiometabolic) or expand its Diagnostics automation menu.
Has Roche divested major divisions to optimize its portfolio?
Yes, Roche divested its Vitamins and Fine Chemicals division to DSM in 2003 for €2.25 billion and sold its Over-the-Counter (OTC) consumer health business (including Aleve, Bepanthen, and Redoxon) to Bayer in 2004 for €2.4 billion.
Does Roche face antitrust regulatory pushback on its acquisitions?
Due to its large market presence in oncology and diagnostics, transactions like Spark Therapeutics and GenMark underwent rigorous reviews by the US Federal Trade Commission (FTC) and UK Competition and Markets Authority (CMA) before securing unconditional clearance.
Related Companies
Compare F. Hoffmann-La Roche AG With Competitors
Related M&A Histories
Compare corporate acquisition records, deal values, and strategic targets
Explore Roche
Core profile pages, founders and related research hubs for this company.